Article History
Received: 15 August 2023
Accepted: 18 March 2024
First Online: 3 April 2024
Declarations
:
: Yoshinobu Kondo received honoraria for lectures from Novo Nordisk Pharma. Shinobu Satoh received honoraria for lectures from Novo Nordisk Pharma and Eli Lilly. Yasuo Terauchi received honoraria for lectures from MSD; Ono Pharmaceutical; Nippon Boehringer Ingelheim; Mitsubishi Tanabe Pharma; Daiichi Sankyo; Kowa; Novo Nordisk Pharma; Eli Lilly; Sanofi; Sumitomo Pharma; Bayer, and AstraZeneca, and has obtained research support from Nippon Boehringer Ingelheim; Mitsubishi Tanabe Pharma; Daiichi Sankyo; Eli Lilly; Sanofi; and Sumitomo Pharma.
: The protocol for this study was approved by the Institutional Review Board of Yokohama City University (date of approval: November 24, 2016, approval No. B161110001) and Chigasaki Municipal Hospital (date of approval: November 18, 2016, approval No. 2016-09), and this study was also registered in the clinical trial registry (University hospital Medical Information Network Clinical Trials Registry 000024164). All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and/or with the Helsinki Declaration of 1964 and later versions.
: All participants were fully informed of the aims and conduct of the study. Written informed consent was obtained from all participants prior to enrollment.